These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 25517302

  • 1. Physicochemical characterization of Remsima.
    Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ.
    MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
    [Abstract] [Full Text] [Related]

  • 2. A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.
    Pisupati K, Tian Y, Okbazghi S, Benet A, Ackermann R, Ford M, Saveliev S, Hosfield CM, Urh M, Carlson E, Becker C, Tolbert TJ, Schwendeman SP, Ruotolo BT, Schwendeman A.
    Anal Chem; 2017 May 02; 89(9):4838-4846. PubMed ID: 28365979
    [Abstract] [Full Text] [Related]

  • 3. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, Lee S, Kim S, Eliakim R, Chowers Y.
    Gut; 2016 Jul 02; 65(7):1132-8. PubMed ID: 25897019
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
    Jha A, Upton A, Dunlop WC, Akehurst R.
    Adv Ther; 2015 Aug 02; 32(8):742-56. PubMed ID: 26343027
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J, Kaasen Jørgensen K.
    Dig Dis; 2017 Aug 02; 35(1-2):83-90. PubMed ID: 28147374
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.
    Layegh Z, Ruwaard J, Hebing RCF, L' Ami MJ, van der Weele W, Nurmohamed MT, Krieckaert C, Wolbink G.
    Int J Rheum Dis; 2019 May 02; 22(5):869-873. PubMed ID: 30767391
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML, Pesce A, Bès C, Seigelchifer M.
    BioDrugs; 2019 Jun 02; 33(3):307-319. PubMed ID: 30927214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.